FindTrial
Sign In

ADMINISTRATION S EFFECTS OF L-ARGININE AND N-ACETYLCYSTEINE ON NITRIC OXIDE S PRODUCTION AND ON BLOOD PRESSURE IN DIABETIC AND HYPERTENSIVE PATIENTS.

ADMINISTRATION S EFFECTS OF L-ARGININE AND N-ACETYLCYSTEINE ON NITRIC OXIDE S PRODUCTION AND ON BLOOD PRESSURE IN DIABETIC AND HYPERTENSIVE PATIENTS.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2004-004203-38-IT
Enrollment
Unknown
Registered
2007-01-05
Start date
2004-12-30
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

DIABETES MELLITUS AND HYPERTENSION MedDRA version: 9.1 Level: LLT Classification code 10012613 Term: Diabetes mellitus non-insulin-dependent MedDRA version: 9.1 Level: LLT Classification code 10004254 Term: Benign essential hypertension

Interventions

Trade Name: ACETILCIST.EG*20CPR EFF 600MG Pharmaceutical Form: Effervescent tablet INN or Proposed INN: Acetylcysteine CAS Number: 616-91-1 Concentration unit: mg milligram(s) Concentration type: equa

Sponsors

AZIENDA SANITARIA OSPEDALIERA S. GIOVANNI BATTISTA DI TORINO
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026